Several studies have confirmed increased cardiovascular risk associated with rofecoxib and diclofenac, and general treatment recommendations include caution with NSAIDs and avoidance of selective COX2-inhibtors if possible [15], [21], [22] Indeed, patients with established cardiovascular disease or patients at increased cardiovascular risk seem to be more vulnerable to the cardiovascular toxicity of NSAIDs. The gene discussed is PTGS2; the disease is cardiovascular disorder.